Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lymphoma, Large B-Cell, Diffuse 25Lymphoma 11Prostatic Neoplasms 9Lymphoma, Non-Hodgkin 9Lymphoma, T-Cell, Peripheral 8Lymphoma, Follicular 7Leukemia 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Multiple Myeloma 5Neoplasms, Plasma Cell 4Lymphoma, Mantle-Cell 4Hodgkin Disease 3Burkitt Lymphoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Myasthenia Gravis 2Lymphoma, Large-Cell, Immunoblastic 2Immunoblastic Lymphadenopathy 2Subcutaneous panniculitis-like T-cell lymphoma 1Spinal Cord Neoplasms 1Recurrence 1Prostatic Neoplasms, Castration-Resistant 1Plasmablastic Lymphoma 1Pituitary Neoplasms 1Neoplasms, Experimental 1Neoplasms 1Neoplasm Metastasis 1Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel 1Neoadjuvant Therapy 1Myelodysplastic Syndromes 1Lymphoma, T-Cell 1

Interventions

Docetaxel 2Sunitinib 1Prednisone 1PE regimen 1Injections 1Etoposide 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Hormone Refractory Prostate Cancer × Prednisone × Clear all
NCT02208583 2014-08-05

Molecular Phenotype Changes and Personalized Treatment for CRPC

Tianjin Medical University Cancer Institute and Hospital

Phase NA Unknown
150 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡